Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine 253 Extended Dual Antiplatelet for Diabetic Elderly Patients After Drug-eluting Stent Implantation: an Evidence-based Clinical Review

ACTA MEDICA INDONESIANA · Vol. 47 No. 3 (2015)

ISSN
2338-2732, 0125-9326
Terbit
2015-07-01
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Antiplatelet is an important drug for patients with coronary heart disease undergoing drug-eluting stent implantation. Current guidelines recommend dual antiplatelet with aspirin and a P2Y12 inhibitor for at least 12 months. Continuation of DAPT beyond 12 months may be considered for preventing very late stent thrombosis. Several patient-related factors that contribute to stent thrombosis have been recognized, including diabetes and advanced age, but the optimal DAPT duration for these patients is still controversial. This article reviews the efficacy of extended (>12 months) compared to standard (12 months) DAPT for reducing myocardial infarction and stent thrombosis rates, especially in diabetic elderly patients. Literature screening was conducted at PubMed and Cochrane database using “dual antiplatelet”, “duration”, “adult-onset diabetes mellitus”, “elderly” and, “drug-eluting stent” as keywords. Article types were limited to meta-analysis, systematic review, randomized clinical trial, or clinical trial that compared the efficacy of extended to standard duration of DAPT. Clinical outcomes used were myocardial infarction and stent thrombosis. The initial search was done to find relevant studies specifically assessing diabetic and elderly patients, then widened to diabetic and non-diabetic patients of any age above eighteen years. A total of 5 clinical trials and 1 meta-analysis were reviewed, showing an overall risk reduction of stent thrombosis and myocardial infarction. This review has several limitations, such as its potential selection bias and underrepresented proportion of diabetic and elderly patients. High-risk subgroups like diabetes mellitus has a tendency of increased ischemic risk, while advanced age could have both increased ischemic risk and bleeding risk. This review suggests that it is better to reserve extended dual antiplatelet therapy for patients with high ischemic risk and low bleeding risk (tailored therapy).Key words: adult-onset diabetes mellitus, drug-eluting stent, extended dual antiplatelet, elderly, myocardial infarction, stent thrombosis.

Jaringan kolaborasi para penulis

40 penulis · 196 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Siti SetiatiAfiliasi tidak diketahui4
Kuntjoro HarimurtiAfiliasi tidak diketahui2
Idrus AlwiAfiliasi tidak diketahui2
Sally A NasutionAfiliasi tidak diketahui1
Birry KarimAfiliasi tidak diketahui1
Euphemia SetoAfiliasi tidak diketahui1
Tirza Z TaminAfiliasi tidak diketahui1
Mulyadi M DjerAfiliasi tidak diketahui1
Nikmah S IdrisAfiliasi tidak diketahui1
Hamzah ShatriAfiliasi tidak diketahui1
Azri NurizalAfiliasi tidak diketahui1
Dono AntonoAfiliasi tidak diketahui1
Rachmat HamonanganAfiliasi tidak diketahui1
Nur RiviatiAfiliasi tidak diketahui1
Murdani AbdullahAfiliasi tidak diketahui1
Dyah PurnamasariAfiliasi tidak diketahui1
Anandhara Indriani KhumaediAfiliasi tidak diketahui1
Yuniarti SoerosoAfiliasi tidak diketahui1
Siti MarhamahAfiliasi tidak diketahui1
Bambang SetyohadiAfiliasi tidak diketahui1
A ArianeAfiliasi tidak diketahui1
Gunawan TirtarahardjaAfiliasi tidak diketahui1
Fragma Ady SukmaAfiliasi tidak diketahui1
P NugrohoAfiliasi tidak diketahui1
Ikhwan RinaldiAfiliasi tidak diketahui1
Rensa RensaAfiliasi tidak diketahui1
Suhendro SuhendroAfiliasi tidak diketahui1
Cleopas M RumendeAfiliasi tidak diketahui1
Cosphiadi IrawanAfiliasi tidak diketahui1
Ceva W PitoyoAfiliasi tidak diketahui1
Fera IbrahimAfiliasi tidak diketahui1
Ari Fahrial SyamAfiliasi tidak diketahui1
Benny ZulkarnainAfiliasi tidak diketahui1
Nuri D IndrasariAfiliasi tidak diketahui1
Dita AditianingsihAfiliasi tidak diketahui1
Adityo SusiloAfiliasi tidak diketahui1
Menaldi RasminAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine 253 Extended Dual Antiplatelet for Diabetic Elderly Patients After Drug-eluting Stent Implantation: an Evidence-based Clinical Review</dc:title>
	<dc:creator>Suwita, Benedicta M</dc:creator>
	<dc:creator>Laksmi, Purwita W</dc:creator>
	<dc:creator>Wijaya, Ika P</dc:creator>
	<dc:description xml:lang="en-US">Antiplatelet is an important drug for patients with coronary heart disease undergoing drug-eluting stent implantation. Current guidelines recommend dual antiplatelet with aspirin and a P2Y12 inhibitor for at least 12 months. Continuation of DAPT beyond 12 months may be considered for preventing very late stent thrombosis. Several patient-related factors that contribute to stent thrombosis have been recognized, including diabetes and advanced age, but the optimal DAPT duration for these patients is still controversial. This article reviews the efficacy of extended (&amp;gt;12 months) compared to standard (12 months) DAPT for reducing myocardial infarction and stent thrombosis rates, especially in diabetic elderly patients. Literature screening was conducted at PubMed and Cochrane database using “dual antiplatelet”, “duration”, “adult-onset diabetes mellitus”, “elderly” and, “drug-eluting stent” as keywords. Article types were limited to meta-analysis, systematic review, randomized clinical trial, or clinical trial that compared the efficacy of extended to standard duration of  DAPT. Clinical outcomes used were myocardial infarction and stent thrombosis. The initial search was done to find relevant studies specifically assessing diabetic and elderly patients, then widened to diabetic and non-diabetic patients of any age above eighteen years. A total of 5 clinical trials and 1 meta-analysis were reviewed, showing an overall risk reduction of stent thrombosis and myocardial infarction. This review has several limitations, such as its potential selection bias and underrepresented proportion of diabetic and elderly patients. High-risk subgroups like diabetes mellitus has a tendency of increased ischemic risk, while advanced age could have both increased ischemic risk and bleeding risk. This review suggests that it is better to reserve extended dual antiplatelet therapy for patients with high ischemic risk and low bleeding risk (tailored therapy).Key words: adult-onset diabetes mellitus, drug-eluting stent, extended dual antiplatelet, elderly, myocardial infarction, stent thrombosis.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2015-07-01</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/41</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 47 No. 3 (2015)</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/41/39</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2016 Indonesian Journal of internal Medicine</dc:rights>
</oai_dc:dc>